CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease

Journal of Alzheimer's Disease

Volumn 21, Issue 2, 2010, Pages 569-576

  Van Eijk, Jeroen J J ^a   Van Everbroeck, Bart ^b   Abdo, W Farid ^a   Kremer, Berry P H ^a,c   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; cerebrospinal fluid; Creutzfeldt Jakob disease; diagnosis; prion disease

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTOSIS; AXONAL INJURY; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; HEAVY CHAIN; HUMAN; MACROGLIA; MAJOR CLINICAL STUDY; MALE; NEUROFILAMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 77957364704     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-090649     Document Type: Article

References (30)

1. De Jong D, Kremer BPH, Olde Rikkert MGM, Verbeek MM (2007) Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med 45, 1421-1434.
2. World Health Organization (1998) Global surveillance, diagnosis, and therapy of human transmissible spongiform encephalopathies: Report of WHO consultation. WHO, Geneva 1998. WHO/EMC/ZDI/98.9., http://www.who.int/topics/ creutzfeldtjakobsyndrome/en/
3. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mäder M, Weber T (1997) S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 244, 566-570. (Pubitemid 27464102)
4. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67, 637-643.
5. Rosengren LE, Karlsson JE, Sjögren M, Blennow K,Wallin A (1999) Neurofilament protein levels are increased in dementia. Neurology 52, 1090-1093.
6. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A (2000) Cytoskeleton proteins in CSF distinguish frontotemopral dementia from AD. Neurology 54, 1960-1964.
7. De Jong D, Jansen RW, Pijnenburg YA, van Geel WJ, Borm GF, Kremer BP, Verbeek MM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 78, 936-938.
8. Liberski PP, Budka H (1999) Neuroaxonal pathology in Creutzfeldt-Jacob disease. Acta Neuropathologica 97, 329-334.
9. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
10. Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin JJ, Cras P (2004) Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 251, 298-304.
11. Van Geel WJA, de Reus HPM, Nijzing H, Verbeek MM, Vos PE, Lamers KJB (2002) Measurement of Glial Fibrillary Acidic Protein in blood: An analytical method. Clin Chim Acta 326, 151-154.
12. Van Geel WJA, Rosengren LR, Verbeek MM (2005) An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 296, 179-185.
13. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM(2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 28, 742-747.
14. Petzold A (2005) Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233, 283-298.
15. Sjögren M, Blomberg M, Jonsson M,Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A (2001) Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J Neurosci Res 66, 510-516.
16. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jacob disease. Neurology 58, 192-197.
17. Nagele RG, Venkataraman V, Imaki H, Wang KC, Wegiel J (2004) Contribution of glial cells to the development of amyloid plaques in AD. Neurobiol Aging 25, 663-674.
18. Aoki T, Kobayashi K, Isaki K (1999) Microglial and astrocytic change in brains of Creutzfeldt-Jakob disease: An immunocytochemical and quantitative study. Clin Neuropathol 18, 51-60.
19. Jesse S, Steinacker P, Cepek L, von Arnim C, Tumani H, Lehnert S, Kretzschmar HA, Baier M, Otto M (2009) Glial fibrillary acidic protein and protein S100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 17, 541-551.
20. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74, 1210-1214.
21. Ladogana A, Sanchez-Juan P, Mitrová E, Green A, Cuadrado-Corrales N, Sánchez-Valle R,Koscova S, Aguzzi A, Sklaviadis T, Kulczycki J, Gawinecka J, Saiz A, Calero M, van Duijn CM, Pocchiari M, Knight R, Zerr I (2009) Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 256, 1620-1628.
22. Bahl JM, Heegaard NH, Falkenhorst G, Laursen H, Høgenhaven H, Mølbak K, Jespersgaard C, Hougs L, Waldemar G, Johannsen P, Christiansen M (2009) The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging 30, 1834-1841.
23. Beaudry P, Cohen P, Brandel JP, Delasnerie-Lauprêtre N, Richard S, Launay JM, Laplanche JL (1999) 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 10, 40-46.
24. Collins S, Boyd A, Fletcher A, Gonzales M, Mc Lean CA, Byron K, Masters CL (2000) Creutzfeldt-Jakob disease: Diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 7, 203-208.
25. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, Green A (2009) The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt- Jakob disease. Neurosci Lett 455, 56-59.
26. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz Bremón A, Budka H, Laplanche JL,Will RG, Poser S (2000) Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55, 811-815.
27. Lemstra AW, van Meegen MT, Vreyling JP, Meijerink PH, Jansen GH, Bulk S, Baas F, van GoolWA(2000) 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients. Neurology 55, 514-516.
28. Zerr I, Bodemer M, Räcker S, Grosche S, Poser S, Kretzschmar HA, Weber T (1995) Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt- Jakob disease. Lancet 345, 1609-1610.
29. Jansen C, Schuur M, Spliet WGM, van Gool WA, van Duijn CM, Rozemuller AJM (2009) Elf jaar obducties wegens de ziekte van Creutzfeldt-Jakob in Nederland. Ned Tijdschr Geneeskd 153, A172.
30. Sanchez-Juan P, Sánchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrová E, Stoeck K, Sklaviadis T,Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichová D, Saiz A, Calero M, Pocchiari M, Knight R, van Duijn CM, Zerr I (2007) Influence of timing on CSF tests value for Creutzfeldt- Jakob disease diagnosis. J Neurol 254, 901-906.